In this study, we examined plasma from HCV-infected participants, and a small cohort who initiated DAA therapy, for indices of inflammation (IL-6, IP10, sCD163, sCD14) and endotoxemia (Endocab, LBP, FABP). This evidence concerns the gene CXCL10 and serum lipopolysaccharide activity.